Abstract: A method and associated system. In response to a request to deploy a virtual machine in a computing environment, a virtual machine resource usage pattern having attributes matching a subset of attributes in than ordered sequence of attributes is selected from at least one virtual machine resource usage pattern stored in a virtual machine resource usage pattern library, based on an ordering of the attributes in the ordered sequence of attributes, wherein the virtual machine resource usage pattern library stores usage patterns for virtual machines previously deployed. A node on which the virtual machine is to be deployed is selected, based on the selected virtual machine resource usage pattern and predicted runtime resource requirements of the virtual machine to be deployed based on historical running data of virtual machines. The virtual machine is configured for being deployed on the selected node. The virtual machine is deployed on the selected node.

Abstract: Provided herein are 5-fluorouridine monophosphate cyclic triester compounds, their preparation and their uses, such as treating hepatocellular carcinoma and other types of cancer.

Abstract: Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof.

Abstract: Provided herein are compounds that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.

Abstract: Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.

Abstract: Provided herein are cyclic phosphorus-containing prodrug compounds, their preparation and their uses, such as treating diseases via modulating molecular targets in the liver.

Abstract: Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.

Abstract: Provided herein are compounds, such as compounds of Formula I, that bind to androgen receptors and/or modulate activity of androgen receptors. Also provided are methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.

Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.

Abstract: Provided herein are cyclic phosphorus-containing prodrug compounds, their preparation and their uses, such as treating diseases via modulating molecular targets in the liver.

Abstract: Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof.

Abstract: Compounds and methods in the fields of chemistry and medicine are disclosed. Some of the disclosed embodiments include compounds, compositions and methods of using heterocycle amines. Some of the disclosed embodiments include heterocycle amines useful to treat inflammatory disorders.

Abstract: Some embodiments include methods for treating, preventing, reversing, halting, or slowing the progression of cancer, comprising administering to a subject in need thereof an effective amount of one or more chemotherapeutic agents, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, wherein at least one of the chemotherapeutic agents is a cytotoxic granulocyte colony-stimulating factor receptor (GCFR) modulator. Methods are also disclosed for treating, preventing, reversing, halting, or slowing the progression of a hematopoietic disorder, comprising administered a therapeutically effective cytotoxic amount of a GCFR modulator to a subject in need thereof.

Abstract: Some embodiments of the present invention include nucleoside 5?-monophosphate derivative compounds, their preparation and their uses. In some embodiments, such compounds are useful to treat hepatitis C viral infections.

Abstract: Provided herein are cyclic phosphorus-containing prodrug compounds, their preparation and their uses, such as treating diseases via modulating molecular targets in the liver.

Abstract: Some embodiments include methods for treating, preventing, reversing, halting, or slowing the progression of cancer, comprising administering to a subject in need thereof an effective amount of one or more chemotherapeutic agents, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, wherein at least one of the chemotherapeutic agents is a cytotoxic granulocyte colony-stimulating factor receptor (GCFR) modulator. Methods are also disclosed for treating, preventing, reversing, halting, or slowing the progression of a hematopoietic disorder, comprising administered a therapeutically effective cytotoxic amount of a GCFR modulator to a subject in need thereof.

Abstract: Compositions and methods in the field of medicine and chemistry are disclosed. Some of the disclosed embodiments are directed to nucleotide compounds, medicinal compositions, as well as processes for their preparation and methods of their use. In some embodiments, such nucleotide compounds are useful antiviral and antimetabolic agents.

Abstract: A method and associated system. A request to deploy a virtual machine in a computing environment is received. The request identifies an ordered sequence of attributes that the virtual machine to be deployed includes. In response to the request, a virtual machine resource usage pattern having attributes matching a subset of attributes in the ordered sequence of attributes is selected, based on an ordering of the attributes in the ordered sequence of attributes. A node on which the virtual machine is to be deployed is selected from two or more nodes in the computing environment, based on the selected virtual machine resource usage pattern and predicted runtime resource requirements of the virtual machine to be deployed.

Abstract: Some embodiments of the present invention include nucleoside 5?-monophosphate derivative compounds, their preparation and their uses. In some embodiments, such compounds are useful to treat hepatitis C viral infections.

Abstract: A method and associated system. In response to a request to deploy a virtual machine in a computing environment, a virtual machine resource usage pattern having attributes matching a subset of attributes in than ordered sequence of attributes is selected from at least one virtual machine resource usage pattern stored in a virtual machine resource usage pattern library, based on an ordering of the attributes in the ordered sequence of attributes, wherein the virtual machine resource usage pattern library stores usage patterns for virtual machines previously deployed. A node on which the virtual machine is to be deployed is selected, based on the selected virtual machine resource usage pattern and predicted runtime resource requirements of the virtual machine to be deployed based on historical running data of virtual machines. The virtual machine is configured for being deployed on the selected node. The virtual machine is deployed on the selected node.